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Abstract Data on prasugrel use in Japanese patients are
limited to phase II/III clinical trials. This early postmar-
keting observational study evaluated the safety and efficacy
of short-term prasugrel use in patients with acute coronary
syndrome (ACS) in real-world clinical settings in Japan.
From May 2014 to January 2015, we enrolled consecutive
patients with ACS requiring percutaneous coronary inter-
vention in each institution. Each patient started prasugrel
treatment C1 month before the end of the study period.
Safety outcomes included incidence rates of adverse drug
reactions (ADRs) and bleeding adverse events (AEs).
Efficacy outcomes were incidence rates of cardiovascular
events (including major adverse cardiovascular events
[MACE]). Case report forms were collected from 749
patients, 732 of whom were eligible for the safety and
efficacy analysis sets. Approximately 95% of patients had a
prasugrel loading/maintenance dose of 20 mg/
3.75 mg/day. The incidences of ADRs and bleeding AEs
were 8.6 and 6.4%, respectively. Twelve patients
experienced major bleeding AEs; approximately 60%
(seven patients) of which were gastrointestinal disorders.
The incidence of bleeding AEs was significantly higher
primarily in patients of female sex, aged C75 years, with
low body weight (B50 kg), severe cardiovascular disease,
or severe renal impairment. The incidence of MACE was
1.9% during prasugrel treatment, and 3.1% at the end of the
study period. This short-term study indicated that prasugrel
treatment at loading/maintenance doses of 20 mg/
3.75 mg/day was safe and effective in Japanese ACS
patients in an acute setting.
Clinical Trial Registration: This study is registered at
http://www.umin.ac.jp/ctr/ under the identifier
UMIN000014699.
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Introduction
To avoid complications after percutaneous coronary inter-
vention (PCI), such as acute and late thrombosis at the site
of stenting and recurrent ischemic cardiovascular events,
anti-platelet therapy is crucial [1]. Several studies [2–4]
have shown that dual anti-platelet therapy with aspirin and
a thienopyridine ADP-receptor blocker is effective in pre-
venting such acute and late complications. Clopidogrel is
an ADP-receptor blocker that is used regularly in Japan. It
has a better safety profile than ticlopidine, a previous-
generation ADP-receptor blocker, but its main disadvan-
tage is the wide interindividual variations of its anti-platelet
effect [5]. Hoshino et al. evaluated the anti-platelet effect
of clopidogrel in Japanese patients and found wide
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interindividual variation as well as a proportion (approxi-
mately 14%) of clopidogrel non-responders [6].
Prasugrel is a next-generation thienopyridine anti-pla-
telet agent that has been approved in over 80 countries for
patients with acute coronary syndrome (ACS) undergoing
PCI. Prasugrel provides more prompt, potent, and consis-
tent platelet inhibition than clopidogrel, and the effects of
prasugrel are not influenced by the presence of CYP2C19
polymorphisms [7]. The efficacy and safety of prasugrel
were confirmed in Japanese patients in two phase III
studies [8, 9]. Based on these results, prasugrel was
approved in Japan in March 2014 for ACS [including
unstable angina, non-ST-segment elevation myocardial
infarction (NSTEMI), and ST-segment elevation myocar-
dial infarction (STEMI)], stable angina, and old myocardial
infarction that requires PCI. The approved doses of pra-
sugrel, which are exclusive for Japanese patients, are
20 mg as the initial loading dose (LD) and 3.75 mg/day as
the maintenance dose (MD), which are lower than those
used in Western countries (LD/MD: 60/10 mg/day). Given
the higher average age and lower body weight of Japanese
patients compared with Western patients, we considered
that lower doses of prasugrel may effectively lower the risk
of bleeding during dual anti-platelet therapy in Japanese
patients while maintaining more consistent platelet inhi-
bition than clopidogrel.
At present, data on the safety and efficacy of prasugrel
in Japanese patients are limited to the populations of the
phase II/III clinical trials, in which patients were selected
based on strict inclusion criteria. In addition, because
bleeding adverse events (AEs) have been reported as the
most common adverse drug reactions (ADRs) in clinical
trials, safety information should be made available in
clinical settings as soon as possible by determining the
incidence and severity of bleeding AEs under actual con-
ditions of use. Therefore, this early postmarketing obser-
vational study (PRASFIT-Practice I) aimed to evaluate the
safety and efficacy of the short-term use of prasugrel in




Briefly, this study was conducted as a postmarketing
observational study in accordance with the Good Post-
marketing Study Practice Guideline (Ministry of Health,
Labour and Welfare Ordinance No. 171). At each institu-
tion, consecutive patients who met the inclusion criteria
were enrolled prospectively. To gather as much informa-
tion as possible in the period immediately after launch,
retrospective data were collected for patients treated with
prasugrel before the conclusion of the contract with each
institution.
All 98 participating institutions approved the study
protocol. Case report forms (CRFs) were collected for each
patient who started treatment with prasugrel at least
1 month before the end of the study period, between 27
May 2014 and 26 January 2015. Because all patients were
to be followed up until the end of the study period (26
January 2015) regardless of completion or discontinuation
of prasugrel treatment, the observation period varied for
each patient. Patients with ACS who were to undergo or
had recently undergone PCI and had started prasugrel
treatment at least 1 month before the end of the study
period were included in this study.
Dosage and administration
Dosage and administration according to the Japanese pre-
scription label of prasugrel are as follows: prasugrel should
be initiated with a single 20-mg oral dose and then con-
tinued at a 3.75-mg once-daily oral dose as a maintenance
dose [10]. Prasugrel was administered as 3.75- and 5-mg
tablets, in combination with aspirin (81–100 mg/day; up to
324 mg could be used as an LD). Patients receiving a
prasugrel dose of 3.75 mg during approximately 5 days
prior to PCI did not require an initial LD. The extent of the
exposure to prasugrel and the timing of prasugrel admin-
istration (before, during, or after PCI) under the actual
conditions of use were examined.
Study variables
Patient demographics, clinical baseline characteristics,
clinical findings assessed prior to prasugrel treatment (or
before initial PCI), during hospitalization, and at discharge,
and the final diagnosis of ACS were assessed. The extent of
exposure to prasugrel was based on the time and date of
administration of the LD, the MD, the daily dose, the
duration of treatment, and continuation or discontinuation
of treatment. Other variables assessed were use of other
anti-platelet agents/anti-coagulants and other concomitant
medications, invasive procedures other than PCI/coronary
artery bypass graft, initial coronary angiography (CAG)
findings if the patient underwent CAG, timing of prasugrel
administration (before, during, or after PCI), vital signs,
laboratory data, AEs, bleeding AEs, and cardiovascular
events.
Safety and efficacy
The safety outcomes assessed were the incidence of ADRs,
serious ADRs, and bleeding AEs. The incidence of
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bleeding AEs was also assessed by clinical characteristics.
AEs were defined as any unfavorable or unintended sign
(including an abnormal laboratory finding), symptom, or
disease showing a temporal association with the use of the
study drug, irrespective of whether it was considered to be
related to the drug. ADRs were defined as AEs for which a
relationship to prasugrel could not be ruled out. AEs or
ADRs that satisfied the following criteria were classified as
serious: an event which (1) results in death, (2) is life-
threatening, (3) requires hospitalization or prolongation of
hospitalization, (4) results in disability or significant inca-
pacity, (5) has the potential to result in disability or sig-
nificant incapacity, (6) is as serious as any of the outcomes
listed above, or (7) causes a congenital anomaly or birth
defect. Detailed definitions of bleeding and cardiovascular
events are provided in Electronic Supplement 1. Regarding
the incidence of bleeding AEs by clinical characteristics,
we identified clinical characteristics potentially affecting
the incidence of bleeding AEs by comparing patients with
bleeding AEs with those without.
The efficacy outcomes were the incidence of major
adverse cardiovascular events (MACE). MACE was
defined as a composite of cardiovascular death, non-fatal
myocardial infarction (MI), and non-fatal ischemic stroke.
All-cause death, non-fatal stroke, readmission due to ang-
ina pectoris, urgent revascularization, and stent thrombosis
(defined as definite or probable according to the Academic
Research Consortium) were also assessed.
Statistical analysis
The planned sample size was 500 patients based on the
estimated number of patients who were anticipated to
receive treatment with prasugrel and on enrollment feasi-
bility. We enrolled consecutive patients in each institution
to avoid patient selection bias. For each of the safety and
efficacy variables, a point estimate and its 95% confidence
interval (CI) were calculated.
The Chi-square test was used for subgroup analyses to
identify clinical characteristics potentially affecting the
incidence of bleeding AEs. The significance level was set
to a = 0.05 (two-sided). All statistical analyses were per-
formed with SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Patient disposition and baseline demographic
and clinical characteristics
CRFs were collected from 749 patients at 98 institutions
nationwide (Fig. 1). Of these, 732 patients were included in
the safety analysis set, excluding those who fell under
‘‘breaches of contract’’ and ‘‘protocol deviations’’. All 732
patients were included in the efficacy analysis set. The
mean (±standard deviation) observation period was
64.9 ± 73.8 days [median (range) 31.0 (1–531) days],
regardless of continuation or discontinuation of prasugrel
treatment.
Baseline demographic and clinical characteristics of
patients are shown in Table 1. In the study population,
60.0% of patients had STEMI. Furthermore, 6.7% of
patients had severe cardiovascular disease, classified as
Killip Class IV. These patients were excluded from
PRASFIT-ACS [8], a phase III clinical trial conducted in
Japanese patients with ACS.
Regarding other clinical characteristics that were
excluded from the PRASFIT-ACS [8], 5.1% of patients had
a history of ischemic stroke; 2.0% were on dialysis; 2.6%
were concomitantly using warfarin or direct oral anti-co-
agulants (DOACs); and 1.5% were using non-steroidal
anti-inflammatory drugs (NSAIDs). The radial puncture
site was the most common in the present observational
study, though the femoral puncture site was the most
common in PRASFIT-ACS [11].
Treatment status of prasugrel and discontinuations
Treatment status of prasugrel and discontinuations are
shown in Fig. 2. An initial LD was administered to 95.1%
of patients. In the majority of patients, the LD was given
before the initial PCI. In 99.0% of patients, the initial
prasugrel LD was 20 mg. One out of 690 (0.1%) patients
was given an MD of 2.5 mg/day; the remaining patients
received an MD of 3.75 mg once-daily.
Almost one-half of the patients completed or dis-
continued the treatment within 1 month. The most
common reason for discontinuation was switching to
other anti-platelet agents (70.2%, 354/504). Of 504
patients, 40 (7.9%) discontinued prasugrel treatment
because of AEs.
Fig. 1 Patient disposition. ACS acute coronary syndrome
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Table 1 Baseline demographic










Male 560 (76.5) 536 (78.2)
Age (years)
C75 221 (30.2) 165 (24.1)
Mean ± SD 67.0 ± 12.4 65.4 ± 11.4
Median (range) 67 (29–97) 65 (32–95)
Body weight (kg)
B50 94 (12.8) 85 (12.4)
Mean ± SD 63.8 ± 12.5 64.2 ± 12.3
Final diagnosis
STEMI 439 (60.0) 340 (49.6)
NSTEMI 92 (12.6) 187 (27.3)
Unstable angina 198 (27.0) 156 (22.8)
Killip classification
Class I 572 (78.1) NA
Class II 91 (12.4)
Class III 15 (2.0)
Class IV 49 (6.7) Exclusion criteria
Medical history
Prior MI 71 (9.7) 34 (5.0)
Prior revascularizations 92 (12.6) 40 (5.8)
Prior CABG 7 (1.0) 6 (0.9)
Prior TLR 33 (4.5) 15 (2.2)
Prior ischemic stroke 37 (5.1) Exclusion criteria
Complications
Hypertension 559 (76.4) 495 (72.3)
Dyslipidemia 565 (77.2) 516 (75.3)
Diabetes mellitus 267 (36.5) 250 (36.5)
History of smoking 249 (34.0) 273 (39.9)
On dialysis 15 (2.0) Exclusion criteria
Antithrombotic agent
Prasugrel ? aspirin 678 (92.6) 685 (100.0)
Prasugrel ? aspirin ? WF or DOAC 19 (2.6) Exclusion criteria
Prasugrel ? NSAIDs (w/o aspirin) 11 (1.5) Exclusion criteria
Concomitant drug
PPIs 347 (47.4) 282 (41.2)
Stent type
Drug-eluting stent 671 (91.7) 291 (42.5)
Puncture site
Brachial 23 (3.1) 22 (3.2)
Radial 374 (51.1) 285 (41.6)
Femoral 315 (43.0) 366 (53.4)
SD standard deviation, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment
elevation myocardial infarction, MI myocardial infarction, CABG coronary artery bypass graft, TLR target
lesion revascularization, WF warfarin, DOAC direct oral anti-coagulant, NSAIDs non-steroidal anti-in-
flammatory drugs, PPIs proton pump inhibitors, NA not available




The incidence of ADRs was 8.6% (63/732); serious ADRs,
3.4% (25/732); and bleeding AEs, 6.4% (Electronic Sup-
plement 2). The most common ADRs were gastrointestinal
disorders (e.g., gastrointestinal hemorrhage) [3.3% (24/
732)]. The most common serious ADRs were also gas-
trointestinal disorders [2.0% (15/732)]. Table 2 summa-
rizes the breakdown of bleeding AEs. Bleeding AEs
occurred in 6.4% of patients. The most common bleeding
AE was gastrointestinal disorders (2.7%), followed by
general disorders and administration site conditions (1.0%).
Regarding puncture site bleeding (puncture site hemor-
rhage or vessel puncture site hematoma), the puncture site
locations were femoral (three patients), radial (two
patients), femoral ? radial (one patient), and brachial (one
patient). The incidence of major bleeding [thrombolysis in
myocardial infarction (TIMI) criteria] AEs was 1.6%.
Approximately 60% (7/12) of all major bleeding AEs were
gastrointestinal disorders.
Fig. 2 a Timing of loading,
loading dose (LD), and starting
maintenance dose (MD);
b duration of prasugrel
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Table 2 Incidence of bleeding adverse events by severity and site
Item Result
No. of patients in the safety analysis set 732
No. of patients with bleeding AEs 47
No. of bleeding AEs 52
Incidence of patients with bleeding AEs (%) 6.4
No. of patients with major bleeding AEs 12
Incidence of patients with major bleeding AEs (%) 1.6
Type of bleeding AE No. of patients with bleeding AEs; No.
of bleeding AEsa (%)










Blood and lymphatic system
disorders
5 (0.7) 1 3 – 1
Anemia 5 [2] (0.7) 1 3 – 1
Eye disorders 1 (0.1) – – – 1
Conjunctiva hemorrhage 1 [1] (0.1) – – – 1
Cardiac disorder 3 (0.4) – – 3 –
Cardiac tamponade 1 [1] (0.1) – – 1 –
Myocardial hemorrhage 2 [2] (0.3) – – 2 –
Vascular disorders 2 (0.3) – 1 – 1
Hematoma 1 [1] (0.1) – – – 1
Bleeding 1 (0.1) – 1 – –
Respiratory, thoracic and
mediastinal disorders
3 (0.4) 1 2
Epistaxis 1 (0.1) – – 1 –
Hemoptysis 1 (0.1) – – 1 –
Pulmonary hemorrhage 1 [1] (0.1) 1 – – –
Gastrointestinal disorders 20 (2.7) 7 6 6 2
Hemorrhagic intestinal
diverticulum
1 (0.1) – – 1 –
Gastrointestinal hemorrhage 6 [6] (0.8) 3 1 2 –
Gingival bleeding 1 (0.1) – – – 1
Hematemesis 1 (0.1) – 1 – –
Hematochezia 1 (0.1) – – 1 –
Mallory-Weiss syndrome 1 (0.1) – 1 – –
Melena 4 [2] (0.5) – 1 2 1
Rectal hemorrhage 2 [2] (0.3) 2 – – –
Upper gastrointestinal
hemorrhage
1 [1] (0.1) 1 – – –
Large intestinal hemorrhage 1 [1] (0.1) – 1 – –
Duodenal hemorrhage 1 [1] (0.1) 1 – – –
Hemorrhoidal bleeding 1 (0.1) – 1 – –
Skin and subcutaneous tissue
disorders
4 (0.5) – 4 – –
Subcutaneous hemorrhage 4 (0.5) – 4 – –
Renal and urinary disorders 3 (0.4) 1 1 1 –
Hematuria 3 [1] (0.4) 1 1 1 –
General disorders and
administration site conditions
7 (1.0) 2 2 – 3
Puncture site hemorrhage 6 [1] (0.8) 1 2 – 3
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The incidence of bleeding AEs by clinical characteris-
tics is shown in Table 3. The incidence of bleeding AEs
was significantly higher in female patients, patients aged
75 years or older, patients with low body weight (50 kg or
less), patients with severe cardiovascular disease (Killip
Class III or IV), patients without dyslipidemia, and patients
with severe renal impairment (creatinine clearance less
than 30 mL/min). The proportion of female patients
weighing 50 kg or less who experienced bleeding AEs was
40.9% (9/22), compared with 16.0% (4/25) among male
patients with bleeding AEs weighing 50 kg or less. Fur-
thermore, puncture site hemorrhage and subcutaneous
hemorrhage were reported more frequently in female
patients [2.9% (5/172) and 1.7% (3/172), respectively],
than in males [0.2% (1/560) and 0.2% (1/560)]. In contrast,
variations in timing of the initial LD (before, during, or
after PCI) did not significantly affect the occurrence of
bleeding AEs.
Of the above risk factors, each score for the following
five main risk factors [female sex, age of 75 years or older,
low body weight (50 kg or less), severe cardiovascular
disease (Killip Class III or IV), and severe renal impair-
ment (creatinine clearance less than 30 mL/min)] is defined
as 1. We calculated the total risk score and the incidence of
bleeding AEs. By this analysis (Fig. 3), we found that the
bleeding risk increased sharply in patients who had four or
all five risk factors.
Efficacy
The details of the efficacy analysis are shown in Table 4.
The incidence of MACE in the efficacy analysis was 1.9%
during prasugrel treatment, and 3.1% up to the end of the
observation period. Cardiovascular death was the most
common MACE, occurring in 13 patients with an incidence
of 1.8% at the end of the study period. Of these, eight
patients had severe cardiovascular disease (Killip Class
IV). The incidence of all-cause death was 1.1% during
prasugrel treatment and 2.2% up to the end of the study.
Cardiovascular death accounted for approximately three-
fourths of all-cause death.
Discussion
This postmarketing observational study assessed the safety
and efficacy of short-term treatment with prasugrel in
patients with ACS in real-world clinical practice settings in
Japan. We consider that this study provides relevant
information in terms of the efficacy and safety of prasugrel
as we included patients with severe cardiac disease (Killip
IV) (6.7% of patients), history of ischemic stroke (5.1%),
and severe renal impairment (on dialysis) (2.0%), as well
as those concomitantly taking drugs that increase the ten-
dency of bleeding AEs, such as warfarin/DOACs (2.6%) or
NSAIDs (1.5%). Patients having these baseline demo-
graphics and/or taking these concomitant drugs (approxi-
mately one-sixth of the patients) were excluded from
clinical studies in Japan, such as PRASFIT-ACS [8].
In approximately 99% of patients, the initial prasugrel
LD and MD were 20 and 3.75 mg, respectively; 95.1% of
patients received an initial LD. Prasugrel was administered
as described in the package insert [10], and aspirin was
used concomitantly in most patients. Nearly 70% of pra-
sugrel treatment completions or discontinuations occurred
as patients switched to other anti-platelet agents. Because
prasugrel was only allowed to be prescribed for a period of
2 weeks during the first year after its launch, these patients
were prescribed other anti-platelet agents for subsequent
long-term treatment.
Table 2 continued
Type of bleeding AE No. of patients with bleeding AEs; No.
of bleeding AEsa (%)










Vessel puncture site hematoma 1 (0.1) 1 – – –
Injury, poisoning and procedural
complications
3 (0.4) – – – 3
Subcutaneous hematoma 2 (0.3) – – – 2
Wounds 1 (0.1) – – – 1
For SOC, the number of patients with bleeding AEs was tabulated, and for preferred term, the number of bleeding AEs (i.e., the number of
patients for each preferred term) was tabulated. MedDRA/J version 18.1
AEs adverse events, SOC system organ class, TIMI thrombolysis in myocardial infarction
a The number of patients for SOC and the number of bleeding AEs for each preferred term were tabulated. The number of serious bleeding AEs
is specified in square brackets in the applicable cells
Observational study of prasugrel with ACS in Japan
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The incidence of ADRs was 8.6%, and the incidence of
serious ADRs was 3.4%. The highest incidence of ADRs
was for gastrointestinal disorders (3.3%). Most of the
ADRs and serious ADRs were bleeding AEs. A total of 12
patients experienced major bleeding AEs. Approximately
60% (seven patients) of all major bleeding AEs were
gastrointestinal disorders. This finding was consistent with
the observation in a survey of clopidogrel (J-PLACE) in
NSTEMI/unstable angina pectoris patients scheduled to
undergo PCI [12], which suggests that gastrointestinal
Table 3 Incidence of bleeding adverse events by clinical
characteristic




Safety analysis set 732 47 (6.4) –
Sex
Male 560 25 (4.5) \0.0001
Female 172 22 (12.8)
Age (years)
\75 511 22 (4.3) 0.0004
C75 221 25 (11.3)
Body weight (kg)a
B50 94 13 (13.8) 0.0008
[50 610 30 (4.9)
Final diagnosisa
STEMI 439 33 (7.5) 0.4138
NSTEMI 92 3 (3.3)
UAP 198 11 (5.6)
Killip classificationa
Class I 572 29 (5.1) 0.0302
Class II 91 8 (8.8)
Class III 15 2 (13.3)
Class IV 49 7 (14.3)
Prior MIa
Absent 653 44 (6.7) 0.1983
Present 71 2 (2.8)
Prior revascularizationsa
Absent 634 43 (6.8) 0.1951
Present 92 3 (3.3)
Prior CABG
Absent 725 47 (6.5) 0.4862
Present 7 0 (0.0)
Prior TLR
Absent 699 45 (6.4) 0.9312
Present 33 2 (6.1)
Prior ischemic strokea
Absent 688 45 (6.5) 0.3508
Present 37 1 (2.7)
Hypertension
Absent 173 11 (6.4) 0.9694
Present 559 36 (6.4)
Dyslipidemia
Absent 167 20 (12.0) 0.0009
Present 565 27 (4.8)
Diabetes mellitus
Absent 465 28 (6.0) 0.5609
Present 267 19 (7.1)
History of smokinga
Absent 462 36 (7.8) 0.0841
Present 249 11 (4.4)
Table 3 continued





Normal ([80) 299 9 (3.0) 0.0043
Mild ([50 to B80) 238 18 (7.6)
Moderate (C30 to B50) 97 9 (9.3)
Severe (\30) 48 7 (14.6)
Timing of loadinga
Before PCIb 533 37 (6.9) 0.5973
During PCIc 71 3 (4.2)
After PCId 61 3 (4.9)
Prasugrel ? aspirin
Not used 54 3 (5.6) 0.7875
Used 678 44 (6.5)
Prasugrel ? aspirin ? WF or DOAC
Not used 713 45 (6.3) 0.4595
Used 19 2 (10.5)
Prasugrel ? NSAIDs (w/o aspirin)
Not used 721 47 (6.5) 0.3814
Used 11 0 (0.0)
PPIs
Not used 385 23 (6.0) 0.6035
Used 347 24 (6.9)
NSTEMI non-ST-segment elevation myocardial infarction, STEMI
ST-segment elevation myocardial infarction, UAP unstable angina
pectoris, MI myocardial infarction; CABG coronary artery bypass
graft, TLR target lesion revascularization, Ccr creatinine clearance,
WF warfarin, DOAC direct oral anti-coagulant, NSAIDs non-steroidal
anti-inflammatory drugs, PPIs proton pump inhibitors, PCI percuta-
neous coronary intervention
* v2 test
a Body weight, Killip class, prior MI, prior revascularization, prior
ischemic stroke, history of smoking, and timing of loading dose were
unknown in 28, 5, 8, 6, 7, 21, and 31 patients, respectively. Three
patients had a final diagnosis other than STEMI, NSTEMI, or UAP.
Baseline Ccr was not calculated in 50 patients
b Given before the initial balloon passage in PCI
c Given from the initial balloon passage in PCI until discharge from
the PCI room
d Given after discharge from the PCI room
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disorders are the main bleeding AEs in ACS patients.
Therefore, preventive measures for gastrointestinal disor-
ders might be required. Aspirin is highly likely to be a
contributor to the development of these gastrointestinal
disorders [13] and the prevention of low-dose aspirin-as-
sociated upper gastrointestinal injuries by proton pump
inhibitors (PPIs) has been reported [14]. However, in this
study, the proportion of patients receiving PPIs was less
than half (47.4%) of the total population assessed.
Although no significant difference was noted in the inci-
dence of bleeding AEs between patients treated with or
without concomitant PPIs in this study, concomitant use of
PPIs from the start of dual anti-platelet therapy seems
essential for preventing gastrointestinal disorders, espe-
cially in high-risk patients.
The incidence of major bleeding AEs in patients treated
with prasugrel was 1.9% in PRASFIT-ACS [8], and was
slightly lower in this study (1.6%). Furthermore, the inci-
dences of minor bleeding AEs, clinically relevant bleeding
AEs, other bleeding AEs, and all bleeding AEs were all
lower in this study in comparison with PRASFIT-ACS [8].
One possible explanation for these differences is that, in
this study, intraoperative bleeding of the expected amount
associated with invasive procedures, such as PCI, was not
reported as an AE. Another possible explanation is that the
observation period in this study differed from that in
PRASFIT-ACS [8].
Notably, the incidence of bleeding AEs in this study was
significantly higher in female patients and patients with
severe cardiovascular disease (Killip Class III or IV), in
addition to patients aged 75 years or older, patients with
low body weight (50 kg or less), and patients with severe
renal impairment. For the elderly, patients with low body
weight, and patients with severe renal impairment,
Fig. 3 Bleeding adverse events
by number of risk factors. AEs
adverse events, Ccr creatinine
clearance. *The score of the risk
factors was not calculated in 55
patients
Table 4 Incidence of
cardiovascular events
Efficacy outcomes Cumulative incidence (%) N = 732
On treatment Until the end of the
observation period (EAS)
MACE 14 (1.9) 23 (3.1)
CV death 6 (0.8) 13 (1.8)
Non-fatal MI 5 (0.7) 5 (0.7)
Non-fatal ischemic stroke 3 (0.4) 5 (0.7)
All-cause death 8 (1.1) 17 (2.3)
Non-fatal stroke 3 (0.4) 6 (0.8)
Readmission due to angina pectoris 4 (0.5) 8 (1.1)
Revascularization 10 (1.4) 16 (2.2)
Stent thrombosis 2 (0.3) 5 (0.7)
EAS efficacy analysis set, MACE major adverse cardiovascular events, CV cardiovascular, MI myocardial
infarction
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prasugrel treatment should be administered with caution as
specified in the ‘‘Careful Administration’’ section of the
package insert. Women generally have lower body weight
than men, and there are differences in skin tissue structure
between the sexes. Therefore, the fact that a higher pro-
portion of female patients reported subcutaneous hemor-
rhage is likely to be related to these observed sex
differences. In fact, the second most common bleeding AE
was general disorders and administration site conditions
(e.g., puncture site hemorrhage) (1.0%); thus, measures to
prevent puncture site bleeding might also be required.
Results of the MATRIX Access study [15], a clinical trial
conducted in European ACS patients who were about to
undergo CAG and PCI, suggested that radial access com-
pared with femoral access decreased the net AEs through a
reduction in major bleeding AEs and death. Furthermore,
in PRASFIT-ACS, the incidence of puncture site bleeding
during PCI was lower in the radial access route group than
in the femoral access route group [11]. In this study, there
was no difference in the number of patients with puncture
site bleeding AEs between groups undergoing PCI via
different puncture sites, which was likely because the
incidence of patients with puncture site bleeding AEs was
low [1.0% (7/732)], even though it was the second most
common bleeding AE. The reason for the low incidence of
puncture site bleeding AEs may be that—in contrast with
PRASFIT-ACS—the proportion of patients undergoing
PCI via femoral access was lower (43.0%) than that
undergoing PCI via radial access (51.1%). Therefore, radial
access seems more appropriate for preventing puncture site
bleeding. In this study, the timing of the LD did not appear
to significantly affect the incidence of bleeding AEs.
Though the overall incidences of bleeding AEs were
lower in this study in comparison with PRASFIT-ACS [8],
after calculating the total risk score in association with the
incidence of bleeding AEs, we found that the risk of
bleeding increased if patients had four or all five risk fac-
tors: ‘‘female sex’’, ‘‘age of 75 years or older’’, ‘‘body
weight of 50 kg or less’’, ‘‘severe cardiovascular disease’’,
and ‘‘severe renal impairment’’. Another study assessed the
risk of bleeding in patients with ACS undergoing PCI
abroad; these investigators concluded that patients with
ACS have marked variability in the risk of bleeding
according to sex, age, and serum creatinine, among other
factors [16]. A study by Saito et al. [11], which examined
periprocedural bleeding in relation to the access route for
PCI in a Japanese sample, found that sex, body weight, and
age were risk factors, observations that are in line with our
findings. There is a possibility that the risk of bleeding will
increase in the above-mentioned patients. However, an
analysis adjusting for confounding effects on each risk
factor was not performed. Furthermore, as a limited num-
ber of patients with severe cardiac dysfunction were
evaluated in clinical trials (these patients were generally
excluded), these patients will be evaluated in the ongoing
PRASFIT-Practice II study, a long-term observational
study in patients with ischemic heart disease.
The incidence of MACE was lower in the current study
(3.1%) than in PRASFIT-ACS [8] (9.4%). Conversely, the
incidences of cardiovascular death (1.8%), all-cause death
(2.2%), and non-fatal ischemic stroke (0.7%) were
slightly higher in the current study than those in PRAS-
FIT-ACS [8] (1.3, 1.8, and 0.4%, respectively). The
explanation for these differences may involve: (1) the
difference in the duration of the observation period in
each study, and (2) that PRASFIT-Practice I was an
observational study reflecting the clinical use of prasugrel
in a real-world setting. Thus, patients with severe condi-
tions were included, whereas in the PRASFIT-ACS [8],
such cases were excluded. The incidence of non-fatal MI
was low in this study, which may also explain the low
incidence of MACE compared with PRASFIT-ACS [8]. A
possible reason for this may be that naturally occurring
MI as well as events judged according to CAG findings
and markers of myocardial injury, including creatine
kinase-MB, were evaluated in PRASFIT-ACS [8]; how-
ever, only cases of MI reported by investigators under the
actual conditions of use were evaluated as events in this
study.
This study had several limitations. Because the study
was designed as a postmarketing observational study, only
patients treated with prasugrel were evaluated. As this
study aimed to assess the real clinical situation in Japan,
patients were not subjected to strict exclusion criteria. The
observation and follow-up periods varied for each patient.
As this was a short-term study, the results are only appli-
cable to patients treated during a short period. The length
of the observational period was insufficient to collect an
adequate number of cardiovascular events to thoroughly
evaluate safety, especially in terms of risk factors. How-
ever, the long-term observational study ‘‘PRASFIT-Prac-
tice II’’ will address these issues.
Conclusion
Based on the results of this short-term clinical study in
patients with ACS in a real-world acute setting, prasugrel
administration at an LD of 20 mg and MD of 3.75 mg/day
was considered to be acceptable for Japanese patients in
terms of safety and efficacy.
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